The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Purpose
Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differentiate and diagnose MCI and LLD.
Conditions
- Depression
- Mild Cognitive Impairment
Eligibility
- Eligible Ages
- Over 60 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- LLD: Age 60 or over; diagnosis of LLD or symptoms consonant with LLD; PHQ-9 score from 15 to 27 - MCI: Age 60 or over; diagnosis of MCI or self-reported insidious onset and continued worsening of cognitive decline; intact activities of daily living - HC: Age 60 or over
Exclusion Criteria
- Age 59 or younger; history of unresolved neurological or psychiatric conditions; current medications known to affect cognition; history of substance abuse; unable to perform activities of daily living; change in employment status due to condition
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Depression | Seniors diagnosed with late life depression or with a concern of late life depression. | |
| Mild cognitive impairment | Seniors with self-reported decline in cognitive function or with a diagnosis of mild cognitive impairment. | |
| Healthy controls | Seniors with no neurological or psychiatric symptoms or conditions. |
Recruiting Locations
More Details
- Status
- Recruiting
- Sponsor
- Miro Health
